Novo Nordisk Says Mikael Dolsten Won't Seek Election to Board at Friday's Meeting

Core Viewpoint - The drugmaker is convening a special shareholder meeting to vote on a new board appointment following its loss of leadership in the obesity-drug market [1] Company Summary - The company is facing challenges in maintaining its position in the obesity-drug sector, prompting the need for a new board to address these issues [1]